{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:02:50Z","timestamp":1788476570366,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dutch MS Research Foundation","award":["18-1030"],"award-info":[{"award-number":["18-1030"]}]},{"name":"Dutch MS Research Foundation","award":["23-1207"],"award-info":[{"award-number":["23-1207"]}]},{"name":"Treatmeds Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100008358","name":"Brain Foundation Netherlands","doi-asserted-by":"crossref","award":["HA2015.01.05"],"award-info":[{"award-number":["HA2015.01.05"]}],"id":[{"id":"10.13039\/501100008358","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovation Fund Healthcare insurers","award":["B 18-313\/ File 3.798"],"award-info":[{"award-number":["B 18-313\/ File 3.798"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,3,16]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment is the risk of progressive multifocal leukoencephalopathy in patients who are seropositive for the John Cunningham virus (JCV). JCV seroconversion rates increase under natalizumab treatment compared with non-natalizumab using controls. The aim of this study was to assess whether lower natalizumab trough concentrations are associated with reduced JCV seroconversion compared with higher natalizumab trough concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two overlapping cohorts of patients treated with intravenous natalizumab in the Netherlands were combined for this study. JCV seroconversion was assessed during periods of high (\u226515\u2009\u00b5g\/mL) and low (&lt;15\u2009\u00b5g\/mL) natalizumab trough concentrations. Low trough concentrations were mainly the result of trough concentration guided personalised extended interval dosing (EID). The seroconversion rates during high and low trough concentrations were compared using a generalised linear mixed model with a Poisson link function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 357 patients from 21 hospitals in the Netherlands were included. The annual seroconversion rate of 8.4% observed in patients during periods of high trough concentrations (n=226) was 2.32 times higher than the seroconversion rate of 4.8% in patients during periods of low trough concentrations (n=252) (95%\u2009CI=1.32 to 4.08, p=0.0035).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The seroconversion rate observed in patients with MS with low trough concentrations was substantially lower compared with those with high trough concentrations during natalizumab treatment. This emphasises the importance of personalised EID, where intervals between infusions are prolonged to achieve lower natalizumab trough concentrations, to increase drug safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2024-335761","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:00:34Z","timestamp":1742954434000},"page":"1038-1045","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis"],"prefix":"10.1136","volume":"96","clinical-trial-number":[{"clinical-trial-number":"nct04225312","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04260711","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05296161","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4864-1429","authenticated-orcid":false,"given":"Liza M Y","family":"Gelissen","sequence":"first","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7196-9826","authenticated-orcid":false,"given":"Alyssa A","family":"Toorop","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pien M","family":"Schipper","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoitsma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Alrijne Ziekenhuis, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M P E","family":"Zeinstra","sequence":"additional","affiliation":[{"name":"Department of Neurology, Isala Diaconessenhuis Meppel, Meppel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk C","family":"van Rooij","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar E P","family":"van Munster","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amphia Hospital, Breda, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Flevoziekenhuis, Almere, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rijnstate Hospital, Arnhem, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs","family":"Wokke","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke F","family":"Kalkers","sequence":"additional","affiliation":[{"name":"Department of Neurology, OLVG, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin L J","family":"Hoogervorst","sequence":"additional","affiliation":[{"name":"Department of Neurology, St Antonius Hospital, Nieuwegein, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jeroen Bosch Hospital, \u2019s Hertogenbosch, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-5225","authenticated-orcid":false,"given":"Christiaan M","family":"Roosendaal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Slingeland Hospital, Doetinchem, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolijn J","family":"Kragt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Reinier de Graaf Gasthuis, Delft, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Eurelings","sequence":"additional","affiliation":[{"name":"Department of Neurology, Spaarne Gasthuis, Haarlem, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"van Genugten","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ziekenhuisgroep Twente, Almelo, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ommelander Hospital Groningen, Scheemda, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L G F","family":"Sinnige","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Centre Leeuwarden, Leeuwarden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Kloosterziel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wilhelmina Ziekenhuis Assen, Assen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edo P J","family":"Arnoldus","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H","family":"Bouvy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-5864","authenticated-orcid":false,"given":"Eva M","family":"Strijbis","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob van","family":"Oosten","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A","family":"De Jong","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"},{"name":"Quality of Care, Amsterdam Public Health Research Institute, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M J","family":"Uitdehaag","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit I","family":"Lissenberg-Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris C","family":"Loeff","sequence":"additional","affiliation":[{"name":"Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[{"name":"Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"},{"name":"Diagnostic Services, Sanquin Research, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-5381","authenticated-orcid":false,"given":"Zo\u00e9 L E","family":"van Kempen","sequence":"additional","affiliation":[{"name":"Department of Neurology, MS Center, Amsterdam UMC De Boelelaan Site, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2026081401350742000_96.11.1038.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2026081401350742000_96.11.1038.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"2026081401350742000_96.11.1038.3","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12128"},{"key":"2026081401350742000_96.11.1038.4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515599681"},{"key":"2026081401350742000_96.11.1038.5","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350742000_96.11.1038.6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol"},{"key":"2026081401350742000_96.11.1038.7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain","volume":"365","author":"Aladro","year":"2016","journal-title":"J Neurol Sci"},{"key":"2026081401350742000_96.11.1038.8","doi-asserted-by":"crossref","first-page":"1756286421998915","DOI":"10.1177\/1756286421998915","article-title":"High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients","volume":"14","author":"Dwyer","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026081401350742000_96.11.1038.9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology (ECronicon)"},{"key":"2026081401350742000_96.11.1038.10","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512460604"},{"key":"2026081401350742000_96.11.1038.11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult Scler"},{"key":"2026081401350742000_96.11.1038.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332758"},{"key":"2026081401350742000_96.11.1038.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00143-0"},{"key":"2026081401350742000_96.11.1038.14","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026081401350742000_96.11.1038.15","first-page":"e745","article-title":"Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology (ECronicon)"},{"key":"2026081401350742000_96.11.1038.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.01.001"},{"key":"2026081401350742000_96.11.1038.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.02.002"},{"key":"2026081401350742000_96.11.1038.18","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16059","article-title":"Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns","volume":"31","author":"Dwyer","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026081401350742000_96.11.1038.19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1177\/13524585241232274","article-title":"The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis","volume":"30","author":"Krieger","year":"2024","journal-title":"Mult Scler"},{"key":"2026081401350742000_96.11.1038.20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/ene.13355","article-title":"John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients","volume":"24","author":"van Kempen","year":"2017","journal-title":"Eur J Neurol"},{"key":"2026081401350742000_96.11.1038.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312940"},{"key":"2026081401350742000_96.11.1038.22","doi-asserted-by":"publisher","DOI":"10.1177\/1756285614540224"},{"key":"2026081401350742000_96.11.1038.23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2026081401350742000_96.11.1038.24","doi-asserted-by":"crossref","unstructured":"Butzkueven H , Kappos L , Spelman T , et al . No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Ther Adv Neurol Disord 2021;14. doi:10.1177\/17562864211042458","DOI":"10.1177\/17562864211042458"},{"key":"2026081401350742000_96.11.1038.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323472"},{"key":"2026081401350742000_96.11.1038.26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"key":"2026081401350742000_96.11.1038.27","doi-asserted-by":"crossref","first-page":"614715","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front Immunol"},{"key":"2026081401350742000_96.11.1038.28","doi-asserted-by":"crossref","first-page":"117385","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J Neurol Sci"},{"key":"2026081401350742000_96.11.1038.29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:35:17Z","timestamp":1786696517000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jnnp-2024-335761"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335761","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}